Selexipag

Prostacyclin Receptor Agonist — BLOOD AND BLOOD FORMING ORGANS

Key facts

Selexipag is an ofp drug in the Prostacyclin Receptor Agonist class catalogued in DrugCentral. It was first approved by the FDA in 2015. Its mechanism of action is classified as Prostacyclin Receptor Agonists. DrugCentral lists 5 molecular targets, including PTGIR, PTGDR and Ptgir. Recorded indications include Pulmonary arterial hypertension and Thromboembolic pulmonary hypertension.

• Approval status: ofp (first approved 2015 by the FDA).
• Drug class: Prostacyclin Receptor Agonist.
• Mechanism of action: Prostacyclin Receptor Agonists.
• Molecular targets: PTGIR, PTGDR, Ptgir and PTGER4 (5 listed in DrugCentral).
• Indications: Pulmonary arterial hypertension and Thromboembolic pulmonary hypertension.
• ATC code: B01AC27 (Platelet aggregation inhibitors excl. heparin).
• Molecular formula: C26H32N4O4S; molecular weight 496.63 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Pulmonary arterial hypertension
• Thromboembolic pulmonary hypertension

Mechanism & targets

• Mechanism of action (MoA): Prostacyclin Receptor Agonists
• Established pharmacologic class: Prostacyclin Receptor Agonist

Molecular targets (5)

Target	Gene	Action	Activity
Prostacyclin receptor	PTGIR	agonist	Ki 7.70
Prostaglandin D2 receptor	PTGDR	unknown	EC50 7.00
Prostacyclin receptor	Ptgir	agonist	Ki 5.68
Prostaglandin E2 receptor EP4 subtype	PTGER4	agonist	Ki 5.31
Prostaglandin E2 receptor EP2 subtype	PTGER2	agonist	Ki 5.24

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2021-08-25	PMDA	—	NIPPON SHINYAKU Co., Ltd	Yes
2015-12-21	FDA	—	ACTELION PHARMS LTD

ATC classification

ATC code	Therapeutic hierarchy
B01AC27	BLOOD AND BLOOD FORMING ORGANS › ANTITHROMBOTIC AGENTS › ANTITHROMBOTIC AGENTS › Platelet aggregation inhibitors excl. heparin

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Pain in jaw	4740.6
Headache	4364.4
Diarrhoea	1915.7
Dyspnoea	1776.3
Myalgia	1731.0
Fluid retention	1449.8
Hospitalisation	1436.0
Right ventricular failure	1133.6
Dyspnoea exertional	1106.1
Flushing	953.3
Nausea	937.7
Pulmonary hypertension	876.7

Chemical structure

• Molecular formula: C₂₆H₃₂N₄O₄S
• Molecular weight: 496.63 g/mol
• CAS number: 475086-01-2
• InChIKey: QXWZQTURMXZVHJ-UHFFFAOYSA-N
• PubChem CID: 9913767

CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=CN=C(C2=CC=CC=C2)C(=N1)C1=CC=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Selexipag used for?

DrugCentral lists the following indications for Selexipag: Pulmonary arterial hypertension and Thromboembolic pulmonary hypertension.

How does Selexipag work?

Selexipag is classified as Prostacyclin Receptor Agonists; its molecular targets in DrugCentral include PTGIR (agonist), PTGDR, Ptgir (agonist) and PTGER4 (agonist).

When was Selexipag first approved?

Selexipag was first approved by the FDA in 2015.

What drug class does Selexipag belong to?

Selexipag is in the Prostacyclin Receptor Agonist class.

What is the chemical formula of Selexipag?

Selexipag has the molecular formula C26H32N4O4S and a molecular weight of 496.63 g/mol.

Sources

• DrugCentral drug card 5077 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL238804 — compound record and bioactivity
• PubChem CID 9913767 — chemical identifiers
• DrugBank DB11362 — drug record
• FDA UNII 5EXC0E384L — substance identity
• DailyMed: FDA labels for Selexipag — current prescribing information (label search)
• UniProt P43119 (PTGIR) — target protein
• UniProt Q13258 (PTGDR) — target protein
• UniProt P35408 (PTGER4) — target protein
• UniProt P43116 (PTGER2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.